The proinflammatory effect and molecular mechanism of IL-17 in the intestinal epithelial cell line HT-29

Journal of B.U.ON.

Volumn 20, Issue 1, 2015, Pages 120-127

  Zhang, Ming ^a   Wang, Ge ^b   Tao, Yun ^c   Zhang, Hua ^c  

^a Department of Cardiology Central Hospital OfHubei Xiangyang   (China)

^b ZHONGNAN HOSPITAL OF WUHAN UNIVERSITY   (China)

^c Aviation General Hospital of China Medical University   (China)

Author keywords

HT 29; IL 17; Inflammatory bowel disease; TNF

Indexed keywords

CXCL1 CHEMOKINE; CXCL2 CHEMOKINE; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; GRANULOCYTE CHEMOTACTIC PROTEIN 2; INTERLEUKIN 17; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; THORIUM; AUTACOID; CHEMOKINE; MITOGEN ACTIVATED PROTEIN KINASE P38; TRAF3IP2 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR;

ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; HT 29 CELL LINE; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; INFLAMMATION; INTESTINE EPITHELIUM CELL; NEUTROPHIL; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; TH17 CELL; WESTERN BLOTTING; DRUG EFFECTS; EPITHELIUM CELL; GENE EXPRESSION REGULATION; GENE SILENCING; GENETIC TRANSFECTION; GENETICS; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASE; INTESTINE MUCOSA; METABOLISM; PHOSPHORYLATION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME;

CHEMOKINES; EPITHELIAL CELLS; GENE EXPRESSION REGULATION; GENE KNOCKDOWN TECHNIQUES; HT29 CELLS; HUMANS; INFLAMMATION MEDIATORS; INFLAMMATORY BOWEL DISEASES; INTERLEUKIN-17; INTESTINAL MUCOSA; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSFECTION; TUMOR NECROSIS FACTOR RECEPTOR-ASSOCIATED PEPTIDES AND PROTEINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84928705045     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Vera D, Lloyd M (Eds). Inflammatory Bowel Diseases. London: Elsevier Inc, 2014, pp 873-888.
2. Zheng P, Lv S, Zhang J et al. A meta-analysis of ex-traintestinal manifestations of inflammatory bowel disease in Mainland China. World Chin J Dig 2009;17:2217-2220.
3. Khor B, Gardet A, Xavier R J. Genetics and pathogenesis of inflammatory bowel disease. Nature 2011;474:307-317.
4. Knights D, Lassen KG, Xavier RJ. Advances in inflam-matory bowel disease pathogenesis: linking host genetics and the microbiome. Gut 2013 62:1505-1510.
5. Fujino S, Andoh A, Bamba S et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut 2003;52:65-70.
6. Hundorfean G, Neurath MF, Mudter J. Functional relevance of T helper 17 (Thl7) cells and the IL017 cytokine family in inflammatory bowel disease. In- flamm Bowel Dis 2012;18:180-186.
7. Cho JS, Pietras EM, Garcia NC et al. IL-17 is essential for host defense against cutaneous Staphylococcus aureus infection in mice. J Clin Invest 2010;120:1762.
8. Agache I, Ciobanu C, Agache C et al. Increased serum IL-17 is an independent risk factor for severe asthma. Respir Med 2010;104:1131-1137.
9. Wu Y, Zhu L, Liu L et al. Interleukin-17A increases cell migration and MMP-1 expression in human periodontal ligament fibroblasts via p38 MAPK/NF-KB-de- pendent pathway. J Cell Phys 2013;28:110-113.
10. Hering NA, Andres S, Fromm A et al. Transforming growth factor-p, a whey protein component, strengthens the intestinal barrier by upregulating claudin-4 in HT-29/B6 cells. J Nutr 2011;141:783-789.
11. Sergent JA, Paget V, Chevillard S. Toxicity and geno- toxicity of nano-SiO2 on human epithelial intestinal HT-29 cell line. Ann Occup Hygiene 2012;56:622-630.
12. Lucie R, Francois H, Carlos C et al. Endothelial activation enhancing neutrophil IL-17 promotes p38 MAPK-dependent recruitment to sites of inflammation. J Immunol 2010;184:4532-4537.
13. Zhang Y, Liu P, Luo L. The research progress of ThL7 cytokine in the mechanism of inflammatory bowel disease. Chin J Cell Mol Immunol 2012; 28:1110-1113.
14. Lin AM, Rubin CJ, Khandpur R et al. Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis. J Immunol 2011;187:490-500.
15. Biswas PS, Kang K, Gupta S et al. A Murine Autoimmune Model of Rheumatoid Arthritis and Systemic Lupus Erythematosus Associated with Deregulated Production of IL-17 and IL-21//Autoimmunity. Humana Press 2012;7:233-251.
16. Rich P, Sigurgeirsson B, Thaci D et al. Secukinumab in-duction and maintenance therapy in moderate-to-se- vere plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study. Br J Dermatol 2013;168:402-411.
17. Zhang Z, David J, Hinrichs. After interleukin-12p40, are interleukin-23 and interleukin-17 the next therapeutic targets for inflammatory bowel disease?. Int Immunopharmacol 2007;7:409-416.
18. Towne E, Maxwell J, Zhang Y. 0037 Differential roles for IL-23 and IL-17 in inflammatory bowel disease. Cytokine 2012;59:515.
19. Strober W, Fuss IJ. Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases. Gastro-enterology 2011;140:1756-1767.
20. Roussel L, Houle F, Chan C et al. IL-17 promotes p38 MAPK-dependent endothelial activation enhancing neutrophil recruitment to sites of inflammation. J Immunol 2010;184:4531-4537.
21. Griffin GK, Newton G, Tarrio ML et al. IL-17 and TNF-a sustain neutrophil recruitment during inflammation through synergistic effects on endothelial activation. J Immunol 2012;188:6287-6299.
22. Chiricozzi A, Guttman-Yassky E, Suarez-Farinas M et al. Integrative responses to IL-17 and TNF-a in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. J Invest Dermatol 2010;131:677-687.
23. Atsushi T, Junpei K, Kenya T. Transcriptional machinery of TNF-a-inducible YTH domain containing 2 (YTHDC2) gene. Gene 2014;535:24-32.
24. Lee HH, Yoon N, Vo MT et al. Tristetraprolin down-reg-ulates IL-17 through mRNA destabilization. FEBS letters 2012;586:41-46.
25. Li Q, Laumonnier Y, Syrovets T et al. Recruitment of CCR6-expressing Thl7 cells by CCL20 secreted from plasmin-stimulated macrophages. Acta Biochim Biophys Sinica 2013;45:593-600.
26. Meares GP, Ma X, Qin H et al. Regulation of CCL20 expression in astrocytes by IL-6 and IL-17. Glia 2012;60:771-781.
27. Guo Q. The immunoregulation mechanisms of IL-17/IL-17R pathway in the inflammatory bowel disease. Peking: Academy of Military Medical Sciences, 2013: 24-32.
28. Kang Z, Liu L, Spangler R et al. IL-17-induced Actl-mediated signaling is critical for cuprizone-in- duced demyelination. J Neurosci 2012;32:8284-8292.
29. Chang SH, Park H, Dong C. Actl adaptor protein is an immediate and essential signaling component of interleukin-17 receptor. J Biol Chem 2006;281:35603-35607.
30. Kang Z, Wang C, Zepp J et al. Actl mediates IL-17- induced EAE pathogenesis selectively in NG2+ glial cells. Nat Neurosci 2013;16:1401-1408.
31. Frangogiannis NG. Regulation of the inflammatory re-sponse in cardiac repair. Circulation Res 2012;110:159-173.
32. Fabbri M, Paone A, Calore F et al. MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response. Proc Natl Academy Sciences 2012;109:2110-2116.
33. Ullman TA, Itzkowitz SH. Intestinal inflammation and cancer. Gastroenterology 2011;140:1807-1816.
34. IStraus DS. TNFA and IL-17 cooperatively stimulate glucose metabolism and growth factor production in human colorectal cancer cells. Mol Cancer 2013;12:78.
35. De-Simone V, Franze E, Ronchetti G et al. TH17-type cytokines, IL-6 and TNF-A synergistically activate STAT3 and NF-KB to promote colorectal cancer cell growth. Oncogene 2014;286:1-11.
36. Terzic J. Inflammation and colon cancer. Gastroenter-ology 2010;138:2101-2114.